Day One

• Assessing the RLT landscape, providing insights into current target successes and guiding future discovery to accelerate development and patient impact
• Opportunities and challenges for RLT R&D, incl. target identification and prioritization (Understanding the rarity of “ideal” targets like PSMA and somatostatin receptors and the implications for success)
• Defining the strategic fit of RLTs, highlighting how they complement existing oncology modalities and enable precision, combination, and patient-tailored therapies
• Future Landscape: a glimpse to the future development of target selection

New Company for 2026

• Characterizing biodistribution to guide target and candidate selection, enabling early identification of on-target engagement and minimizing off-target liabilities
• Quantifying dosimetry through direct and surrogate imaging approaches, improving radionuclide choice and translational accuracy of absorbed dose estimates
• Integrating multimodal imaging to monitor treatment response, accelerating proof-of-mechanism insights and data-driven optimization of therapeutic design

New Company for 2026

This is your opportunity to get face-to-face with many of the brightest minds in nuclear medicine who are working in preclinical development, medicinal chemistry, target discovery, biology and more.

• Selecting vector, linker, and radionuclide to maximize tumour specificity, retention, and therapeutic index
• Preclinical and manufacturing considerations to ensure scalability, consistency, and early risk reduction
• Achieving the optimal clinical target product profile to drive efficacy, safety, and competitive differentiation in the clinic

New Company for 2026

• Using early biodistribution and dosimetry to guide safe, effective dosing for phase zero/fih trials
• Confirming target specificity preclinically to reduce off-target risks and strengthen your IND package
• Aligning radiochemistry with GMP standards early to avoid delays and ensure clinical readiness

• Allowing more radiation to reach the tumor while sparing healthy tissues
• Combining the strengths of antibodies (long circulation) with small molecules (fast clearance) for safer delivery
• Offering a path to more effective and tolerable treatments and addressing potential complexity in the clinic

New Company for 2026

• Investigating strategies to design peptide-based radiopharmaceuticals that precisely bind desired molecular targets for improved therapeutic efficacy
• Understanding methods to predict and modulate radiation distribution, minimizing off-target exposure and enhancing safety
• Gaining insights into integrating design, preclinical evaluation, and dosimetry planning to streamline progression from concept to clinical application

New Company for 2026

• Expanding radiopharmaceutical reach by drugging first-in-class targets COF-01 and ALT-01
• Optimizing tumor delivery through intelligent ligand design and tunable pharmacokinetics
• Accelerating clinical translation with a data-driven selection and prioritization framework

New Company for 2026

• Improving tumor cell uptake to deliver more effective radiation and therapy
• Combining antibodies against distinct HER2 domains to maximize therapeutic impact
• Expanding treatment options for patients with HER2-positive cancers through additive benefits

New Company for 2026

This is an informal session to help you connect with your peers in a relaxed atmosphere to forge new and beneficial relationships. With an audience of TRP experts working in Discovery, Preclinical Research & Medicinal Chemistry, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge research from drug discovery and preclinical research in radioligand therapy.

• Optimizing pharmacokinetics to maximize tumor uptake and penetration while minimizing off-target exposure and systemic toxicities
• Enhancing therapeutic precision by delivering potent alpha or beta-emitting radioisotopes to selectively destroy cancer cells
• Expanding target scope to address both high- and low-expressing cancer cells, enabling broad applicability across diverse tumor types

New Company for 2026

• Analyzing differential cellular processing of antibodies versus ligands to guide therapeutic strategy
• Comparing biodistribution of antibodies versus ligands to optimize target delivery
• Identifying opportunities for synergistic efficacy to enhance treatment outcomes